All Insurance Policy Changes (Page 459)

Continuing from page 458. Showing older policy changes tracked across all payers. Use the filters in the related-hubs section below to narrow by provider, state, or specialty.

Low impact
Grenz Ray Therapy for Skin Disorders
Blue Cross & Blue Shield of Mississippi·Effective Dec 5, 2024
BCBS Mississippi policy L.8.01.402 confirms that Grenz ray therapy for skin disorders remains classified as investigational and is not covered. This policy was reviewed on 12/05/2024 with no changes to the coverage determination.
Low impact
General Health Panel
Blue Cross & Blue Shield of Mississippi·Effective Dec 5, 2024
BCBS Mississippi has confirmed that General Health Panel (CPT 80050) remains classified as 'not medically necessary' with no coverage changes. This is a routine policy review with no modifications to billing or coverage requirements.
Medium impact
Luteinizing Hormone (LH) Testing
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This is a new medical policy (L.2.04.412) establishing coverage criteria for Luteinizing Hormone (LH) testing. The policy covers LH testing for males with hypogonadism/hypergonadism and females with ovarian dysfunction symptoms, but excludes screening in asymptomatic patients and any fertility-related testing.
Medium impact
Intravenous Nutrient Therapy
Blue Cross & Blue Shield of Mississippi·Effective Dec 6, 2024
BCBS Mississippi updated their policy on Intravenous Nutrient Therapy, removing deleted HCPCS code J0610 from their code reference list. The policy continues to classify IV nutrient therapy as not medically necessary, meaning claims using related codes will be denied.
Medium impact
Immunohistochemistry for Microscopic Evaluation of Prostate Biopsy
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
BCBS Mississippi updated their immunohistochemistry (IHC) staining policy for prostate biopsy evaluation, clarifying when IHC testing is medically necessary versus not reasonable and necessary. The policy specifies that IHC is only covered for suspicious but non-diagnostic H&E stains and certain specific clinical scenarios, while prohibiting routine or reflex IHC testing without pathologist review.
Low impact
Neuromuscular Electrical Stimulation (NMES)
Blue Cross & Blue Shield of Mississippi·Effective Oct 1, 2024
BCBS Mississippi updated their Neuromuscular Electrical Stimulation (NMES) policy with no changes to coverage criteria or billing codes. This is a routine policy review with the most recent update adding HCPCS code E0743 effective October 1, 2024.
Low impact
Needle-Free Insulin Injection Systems
Blue Cross & Blue Shield of Mississippi·Effective Dec 16, 2024
BCBS Mississippi has reaffirmed that needle-free insulin injection systems (jet injectors) remain investigational and not covered. The policy was reviewed on 12/16/2024 with no changes, maintaining the non-coverage status that has been in place since 2001.
Medium impact
Myeloperoxidase (MPO) Immunoassay for Cardiac Disease Risk
Blue Cross & Blue Shield of Mississippi·Effective Dec 16, 2024
This policy confirms that Myeloperoxidase (MPO) immunoassay testing for cardiac disease risk assessment remains classified as investigational and is not covered. The policy was reviewed on 12/16/2024 with no changes, maintaining the investigational status that has been in place since 2013.
Low impact
Motorized Wheelchairs
Blue Cross & Blue Shield of Mississippi·Effective Dec 16, 2024
This is a policy review with no changes to the Motorized Wheelchairs policy. The policy maintains existing coverage criteria for 3 and 4-wheeled motorized wheelchairs, requiring severe mobility impairment, demonstrated operating skills, proper evaluation, and 6+ month expected disability duration.
Medium impact
Monitored Anesthesia Care during Gastrointestinal Endoscopy
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This policy establishes criteria for when monitored anesthesia care (MAC) is medically necessary during gastrointestinal endoscopy procedures. MAC is only covered when specific risk factors are documented by both the endoscopist and anesthesiologist, including ASA class III or higher, morbid obesity (BMI >40), sleep apnea, cognitive dysfunction, or patients under 18 or over 70 years old.
Medium impact
Medically Indicated Early-Term Deliveries (Prior to 39 Weeks)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
BCBS MS updated their medical policy for early-term deliveries prior to 39 weeks, defining specific medical conditions that justify medically necessary early delivery versus elective procedures. The policy provides clear criteria for when induction of labor or cesarean section before 39 weeks is covered versus not medically necessary.
Low impact
Digital Health Technologies: Diagnostic Applications
Blue Cross & Blue Shield of Mississippi·Effective Jan 1, 2025
BCBS has added new HCPCS codes G0552, G0553, and G0554 effective January 1, 2025 for digital health technologies. Canvas Dx, an AI diagnostic aid for autism spectrum disorder, remains classified as investigational and not covered.
Low impact
State and School Employees' Health Insurance Plan - ACTH Gel (Repository Corticotropin Injection)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
New policy for State and School Employees' Health Insurance Plan establishes coverage criteria for ACTH Gel (Repository Corticotropin Injection). The medication is considered medically necessary only for infantile spasms, while use for other corticosteroid-responsive conditions is considered investigational unless patients have contraindications to standard corticosteroids.
Medium impact
ACTH Gel (Repository Corticotropin Injection)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
BCBS Mississippi updated their ACTH Gel (Repository Corticotropin Injection) policy, limiting medically necessary coverage to infantile spasms only. All other FDA-approved indications (multiple sclerosis, rheumatic disorders, etc.) are now considered investigational unless patients have contraindications to standard corticosteroids.
Medium impact
Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Metastatic Colorectal Cancer (KRAS, NRAS, BRAF, and HER2)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This is a new medical policy establishing coverage criteria for somatic biomarker testing (including liquid biopsy) for targeted treatment in metastatic colorectal cancer, specifically for KRAS, NRAS, BRAF, and HER2 testing. The policy provides detailed coverage guidelines for both tissue-based and circulating tumor DNA testing to guide targeted therapy decisions.
Medium impact
Intensity-Modulated Radiotherapy (IMRT): Prostate
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This policy establishes coverage criteria for Intensity-Modulated Radiotherapy (IMRT) for prostate cancer treatment. IMRT is considered medically necessary for localized prostate cancer and post-prostatectomy adjuvant or salvage therapy when specific clinical criteria are met, but investigational when criteria are not satisfied.
Medium impact
Intensity-Modulated Radiotherapy (IMRT): Central Nervous System Tumors
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
Blue Cross Blue Shield Mississippi has updated their IMRT policy for central nervous system tumors, establishing specific medical necessity criteria when tumors are near critical brain structures and 3D conformal radiotherapy cannot meet dose tolerance limits. The policy also covers hippocampal-avoiding IMRT for brain metastases with specific distance and survival requirements.
Medium impact
Extracorporeal Photopheresis
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This is a new Blue Cross Blue Shield Mississippi medical policy defining coverage criteria for Extracorporeal Photopheresis (ECP). The policy establishes when ECP is considered medically necessary versus investigational for cardiac transplant rejection, graft-versus-host disease, and cutaneous T-cell lymphoma treatment.
Medium impact
Radioactive Seed Localization of Nonpalpable Breast Lesions
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
BCBS Mississippi has established a new medical policy for radioactive seed localization of nonpalpable breast lesions. The procedure is considered medically necessary for guiding excisional biopsy or breast-conserving surgery, but may be denied if it costs more than wire localization alternatives due to 'least costly alternative' provisions.
Low impact
Functional Magnetic Resonance Imaging of the Brain for Presurgical Mapping or Seizure Focus Localization
Blue Cross & Blue Shield of Mississippi·Effective Jan 31, 2025
Blue Cross Blue Shield updated policy L.6.01.423 for functional MRI brain imaging, changing the title to specify presurgical mapping and seizure focus localization, and changing the policy number from A.6.01.47. The policy statements for medical necessity remain unchanged - fMRI is covered as complementary testing before neurosurgery when lesions are near eloquent brain areas.
Low impact
Endobronchial Brachytherapy
Blue Cross & Blue Shield of Mississippi·Effective Jan 31, 2025
This is a policy renumbering change for endobronchial brachytherapy coverage, changing from policy number A.8.03.11 to L.8.03.404. The coverage criteria and billing requirements remain unchanged - still considered medically necessary for primary endobronchial tumors not suitable for surgery/external-beam radiation and for palliative treatment of airway obstruction or severe hemoptysis.
Medium impact
Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, NTRK Gene Fusion)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
New policy establishes coverage criteria for germline and somatic biomarker testing (including liquid biopsy) for targeted treatment in prostate cancer, specifically for BRCA1/2, homologous recombination repair gene alterations, and NTRK gene fusion testing. This affects billing for genetic testing and targeted therapies for metastatic castrate-resistant prostate cancer patients.
Medium impact
Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, NTRK)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This is a new comprehensive medical policy covering germline and somatic biomarker testing (including liquid biopsy) for targeted treatment in ovarian cancer, focusing on BRCA1, BRCA2, homologous recombination deficiency, and NTRK testing. The policy establishes coverage criteria and companion diagnostic requirements for various FDA-approved targeted therapies including PARP inhibitors and NTRK fusion inhibitors.
Medium impact
Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This is a fresh policy (1 day old) establishing coverage criteria for somatic biomarker testing including liquid biopsy for targeted treatment in non-small-cell lung cancer, covering multiple genetic markers (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK). The policy provides comprehensive background on genetic testing and FDA-approved targeted therapies but appears to be the introductory section without specific billing codes or coverage determinations.
Medium impact
Non-Pharmacologic Treatment of Rosacea
Blue Cross & Blue Shield of Mississippi·Effective Feb 5, 2025
Blue Cross Blue Shield policy A.2.01.71 confirms that non-pharmacologic treatments for rosacea (laser therapy, dermabrasion, chemical peels, electrosurgery) remain investigational and not covered. No changes were made to the policy statement in the latest review dated 02/05/2025.

Browse by payer Browse by state Browse by specialty Browse by billing code Browse & filter all changes

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Archive by year

2023 2024 2025 2026

Grenz Ray Therapy for Skin Disorders

General Health Panel

Luteinizing Hormone (LH) Testing

Intravenous Nutrient Therapy

Immunohistochemistry for Microscopic Evaluation of Prostate Biopsy

Neuromuscular Electrical Stimulation (NMES)

Needle-Free Insulin Injection Systems

Myeloperoxidase (MPO) Immunoassay for Cardiac Disease Risk

Motorized Wheelchairs

Monitored Anesthesia Care during Gastrointestinal Endoscopy

Medically Indicated Early-Term Deliveries (Prior to 39 Weeks)

Digital Health Technologies: Diagnostic Applications

State and School Employees' Health Insurance Plan - ACTH Gel (Repository Corticotropin Injection)

ACTH Gel (Repository Corticotropin Injection)

Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Metastatic Colorectal Cancer (KRAS, NRAS, BRAF, and HER2)

Intensity-Modulated Radiotherapy (IMRT): Prostate

Intensity-Modulated Radiotherapy (IMRT): Central Nervous System Tumors

Extracorporeal Photopheresis

Radioactive Seed Localization of Nonpalpable Breast Lesions

Functional Magnetic Resonance Imaging of the Brain for Presurgical Mapping or Seizure Focus Localization

Endobronchial Brachytherapy

Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, NTRK Gene Fusion)

Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, NTRK)

Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)

Non-Pharmacologic Treatment of Rosacea